Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

INTRODUCTION: Parkinson’s disease (PD) is a common neurodegenerative disorder with substantial morbidity. No disease-modifying treatments currently exist. The glucagon like peptide-1 receptor agonist exenatide has been associated in single-centre studies with reduced motor deterioration over 1 year....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMJ Open
Glavni autori: Vijiaratnam, Nirosen, Girges, Christine, Auld, Grace, Chau, Marisa, Maclagan, Kate, King, Alexa, Skene, Simon, Chowdhury, Kashfia, Hibbert, Steve, Morris, Huw, Limousin, Patricia, Athauda, Dilan, Carroll, Camille B, Hu, Michele T, Silverdale, Monty, Duncan, Gordon W, Chaudhuri, Ray, Lo, Christine, Del Din, Silvia, Yarnall, Alison J, Rochester, Lynn, Gibson, Rachel, Dickson, John, Hunter, Rachael, Libri, Vincenzo, Foltynie, Thomas
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2021
Teme:
Neurology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8166598/
https://ncbi.nlm.nih.gov/pubmed/34049922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-047993
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items